| 29.96 -0.45 (-1.48%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 37.63 | 1-year : | 43.95 |
| Resists | First : | 32.22 | Second : | 37.63 |
| Pivot price | 30.19 |
|||
| Supports | First : | 28.13 | Second : | 25.61 |
| MAs | MA(5) : | 29.54 |
MA(20) : | 30.13 |
| MA(100) : | 24.39 |
MA(250) : | 29.64 |
|
| MACD | MACD : | 0.8 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 42 |
D(3) : | 30.6 |
| RSI | RSI(14): 55.8 |
|||
| 52-week | High : | 51.61 | Low : | 18.53 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VERA ] has closed above bottom band by 41.6%. Bollinger Bands are 52.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 30.49 - 30.67 | 30.67 - 30.83 |
| Low: | 29.23 - 29.41 | 29.41 - 29.59 |
| Close: | 29.69 - 29.99 | 29.99 - 30.27 |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Wed, 29 Oct 2025
Vera Therapeutics Inc. stock chart pattern explained - 2025 Investor Takeaways & Weekly Consistent Profit Watchlists - newser.com
Wed, 29 Oct 2025
Is Vera Therapeutics Inc. still worth holding after the dip - 2025 Volatility Report & Weekly Chart Analysis and Guides - newser.com
Tue, 28 Oct 2025
How to interpret RSI for Vera Therapeutics Inc. stock - Trade Risk Assessment & Fast Gain Stock Tips - newser.com
Tue, 28 Oct 2025
How to build a custom watchlist for Vera Therapeutics Inc. - Trade Risk Report & Free Technical Pattern Based Buy Signals - newser.com
Tue, 28 Oct 2025
Ranking Vera Therapeutics Inc. among high performing stocks via tools - Weekly Trade Summary & Technical Pattern Based Signals - newser.com
Mon, 27 Oct 2025
How to build a custom watchlist for Vera Therapeutics Inc. - 2025 Top Decliners & Technical Confirmation Trade Alerts - newser.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 110.5 (%) |
| Shares Short | 9,760 (K) |
| Shares Short P.Month | 9,360 (K) |
| EPS | -3.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.3 % |
| Return on Equity (ttm) | -54.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.7 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -185 (M) |
| Levered Free Cash Flow | -112 (M) |
| PE Ratio | -8.35 |
| PEG Ratio | 0 |
| Price to Book value | 4.08 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|